A Study of Avastin (Bevacizumab) in Patients With Multiple Myeloma

Sponsor
Hoffmann-La Roche
Study ID
NCT02079519
Phase
PHASE2
Status
Terminated

Conditions

Eligibility Criteria

Sex
ALL
Age
19 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • Bevacizumab — DRUG
    Bevacizumab was provided as a concentrate in vials.

Study Details

This study evaluated the efficacy and safety of Avastin (bevacizumab, 5 mg/kg intravenously every 2 weeks) in patients with multiple myeloma, relapsed/refractory after at least 2 lines of prior therapy.

Key Dates

First listed
Mar 5, 2014
Start date
May 31, 2006
Status verified
Jun 2014
Primary completion
May 31, 2008
Completion
May 31, 2008

Study Design

Enrollment
10 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Bevacizumab 5 mg/kg
    Participants received bevacizumab 5 mg/kg intravenously every 2 weeks for 6 months until disease progression or termination of the study. Participants showing a continuous benefit of therapy could receive treatment for a maximum of 12 months.

Primary Outcome Measure

Percentage of Participants With a Complete Response or a Partial Response [ Time Frame: Baseline to the end of the study (up to 1 year) ]

Related Studies